By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sales of women's health products helped drive Myriad Genetics' total revenues up 8 percent in the company's fiscal first quarter for 2011, but short of analysts' estimates.

For the three months ended Sept. 30, total revenues increased to $91.9 million, compared to $85.1 million a year ago, helped by an 18 percent jump in revenues related to woman's health products to $25.8 million from $21.8 million, the company reported after the close of market on Tuesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.